Breaking the Gut-Liver Axis: Experimental Drug DT-109 Reverses Severe Fatty Liver Disease in Breakthrough Animal Studies
Executive Overview In a development that could reshape the therapeutic landscape for chronic metabolic conditions, researchers at Michigan Medicine have successfully reversed metabolic dysfunction-associated steatohepatitis (MASH)—a severe, progressive form of…